{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:45:23Z","timestamp":1792100723866,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008485","name":"Schweizerische Akademie der Medizinischen Wissenschaften","doi-asserted-by":"publisher","award":["YTCR 55\/19"],"award-info":[{"award-number":["YTCR 55\/19"]}],"id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00262-020-02768-5","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T09:03:06Z","timestamp":1603875786000},"page":"1089-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"70","author":[{"given":"Johanna","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max M.","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Gassenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette-Triin","family":"Purde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cozzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-2886","authenticated-orcid":false,"given":"Nikolaus B.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"2768_CR1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"2768_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"2768_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"2768_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"key":"2768_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792","journal-title":"J Clin Oncol"},{"key":"2768_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"2768_CR7","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","volume":"35","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807\u20133814","journal-title":"J Clin Oncol"},{"key":"2768_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","volume":"7","author":"P Xing","year":"2019","unstructured":"Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S et al (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 7:341","journal-title":"J Immunother Cancer"},{"key":"2768_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner F, Bomze D, Diem S, Ali OH, Fassler M, Ring S et al (2019) Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 5:1043\u20131047","journal-title":"JAMA Oncol"},{"key":"2768_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206\u20131212","journal-title":"JAMA Dermatol"},{"key":"2768_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45\u201351","journal-title":"JAMA Dermatol"},{"key":"2768_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","volume":"9","author":"HG Reddy","year":"2018","unstructured":"Reddy HG, Schneider BJ, Tai AW (2018) Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol 9:180","journal-title":"Clin Transl Gastroenterol"},{"key":"2768_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","volume":"67","author":"HM McGuire","year":"2018","unstructured":"McGuire HM, Shklovskaya E, Edwards J, Trevillian PR, McCaughan GW, Bertolino P et al (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67:563\u2013573","journal-title":"Cancer Immunol Immunother"},{"key":"2768_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","volume":"81","author":"I Spankuch","year":"2017","unstructured":"Spankuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C et al (2017) Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer 81:203\u2013205","journal-title":"Eur J Cancer"},{"key":"2768_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA et al (2017) Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5:417\u2013424","journal-title":"Cancer Immunol Res"},{"key":"2768_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/20014091084227","volume":"38","author":"JB Whitfield","year":"2001","unstructured":"Whitfield JB (2001) Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38:263\u2013355","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2768_CR17","first-page":"1169","volume":"30","author":"A Corti","year":"2010","unstructured":"Corti A, Franzini M, Paolicchi A, Pompella A (2010) Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 30:1169\u20131181","journal-title":"Anticancer Res"},{"key":"2768_CR18","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.3748\/wjg.v16.i32.4084","volume":"16","author":"XZ Wu","year":"2010","unstructured":"Wu XZ, Ma F, Wang XL (2010) Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 16:4084\u20134088","journal-title":"World J Gastroenterol"},{"key":"2768_CR19","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1111\/codi.12258","volume":"15","author":"WZ He","year":"2013","unstructured":"He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ et al (2013) Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis 15:e443-452","journal-title":"Colorectal Dis"},{"key":"2768_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.urolonc.2018.11.002","volume":"37","author":"K Takemura","year":"2019","unstructured":"Takemura K, Fukushima H, Ito M, Kataoka M, Nakanishi Y, Sakamoto K et al (2019) Prognostic significance of serum gamma-glutamyltransferase in patients with advanced urothelial carcinoma. Urol Oncol 37:108\u2013115","journal-title":"Urol Oncol"},{"key":"2768_CR21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/bjc.2012.16","volume":"106","author":"V Seebacher","year":"2012","unstructured":"Seebacher V, Polterauer S, Grimm C, Rahhal J, Hofstetter G, Bauer EM et al (2012) Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial. Br J Cancer 106:1551\u20131555","journal-title":"Br J Cancer"},{"key":"2768_CR22","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bjc.2014.450","volume":"111","author":"SL Hofbauer","year":"2014","unstructured":"Hofbauer SL, Stangl KI, de Martino M, Lucca I, Haitel A, Shariat SF et al (2014) Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. Br J Cancer 111:1526\u20131531","journal-title":"Br J Cancer"},{"key":"2768_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1151::AID-CNCR20>3.0.CO;2-G","volume":"85","author":"S Eskelin","year":"1999","unstructured":"Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85:1151\u20131159","journal-title":"Cancer"},{"key":"2768_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ajo.2003.08.045","volume":"137","author":"I Kaiserman","year":"2004","unstructured":"Kaiserman I, Amer R, Pe\u2019er J (2004) Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137:236\u2013243","journal-title":"Am J Ophthalmol"},{"key":"2768_CR25","first-page":"351","volume":"31","author":"K Hendler","year":"2011","unstructured":"Hendler K, Pe\u2019er J, Kaiserman I, Baruch R, Kalickman I, Barak V et al (2011) Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res 31:351\u2013357","journal-title":"Anticancer Res"},{"key":"2768_CR26","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.ophtha.2012.01.045","volume":"119","author":"F Mouriaux","year":"2012","unstructured":"Mouriaux F, Diorio C, Bergeron D, Berchi C, Rousseau A (2012) Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma. Ophthalmology 119:1590\u20131595","journal-title":"Ophthalmology"},{"key":"2768_CR27","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM (2013) Challenges of guarantee-time bias. J Clin Oncol 31:2963\u20132969","journal-title":"J Clin Oncol"},{"key":"2768_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071\u20131077","journal-title":"Invest New Drugs"},{"key":"2768_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A et al (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39:1075\u20131084","journal-title":"Am J Surg Pathol"},{"key":"2768_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS et al (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185\u20131192","journal-title":"Cancer Immunol Res"},{"key":"2768_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536","journal-title":"Invest New Drugs"},{"key":"2768_CR32","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV et al (2017) Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2:e000268","journal-title":"ESMO Open"},{"key":"2768_CR33","doi-asserted-by":"publisher","first-page":"6391712","DOI":"10.1155\/2019\/6391712","volume":"2019","author":"K Imoto","year":"2019","unstructured":"Imoto K, Kohjima M, Hioki T, Kurashige T, Kurokawa M, Tashiro S et al (2019) Clinical features of liver injury induced by immune checkpoint inhibitors in japanese patients. Can J Gastroenterol Hepatol 2019:6391712","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2768_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55:653\u2013661","journal-title":"J Gastroenterol"},{"key":"2768_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H et al (2020) Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol 26:353\u2013365","journal-title":"World J Gastroenterol"},{"key":"2768_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/ajco.13317","volume":"16","author":"B Tan","year":"2020","unstructured":"Tan B, Li Y, Xu Y, Chen M, Wang M, Qian J (2020) Recognition and management of the gastrointestinal and hepatic immune-related adverse events. Asia Pac J Clin Oncol 16:95\u2013102","journal-title":"Asia Pac J Clin Oncol"},{"key":"2768_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bcp.2005.10.005","volume":"71","author":"A Pompella","year":"2006","unstructured":"Pompella A, De Tata V, Paolicchi A, Zunino F (2006) Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol 71:231\u2013238","journal-title":"Biochem Pharmacol"},{"key":"2768_CR38","doi-asserted-by":"publisher","first-page":"e47687","DOI":"10.1371\/journal.pone.0047687","volume":"7","author":"HW Hann","year":"2012","unstructured":"Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B et al (2012) Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS ONE 7:e47687","journal-title":"PLoS ONE"},{"key":"2768_CR39","doi-asserted-by":"publisher","first-page":"e61448","DOI":"10.1371\/journal.pone.0061448","volume":"8","author":"YJ Lin","year":"2013","unstructured":"Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY et al (2013) Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS ONE 8:e61448","journal-title":"PLoS ONE"},{"key":"2768_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/etm.2012.783","volume":"5","author":"J Zhu","year":"2013","unstructured":"Zhu J, Jiang F, Ni HB, Xiao MB, Chen BY, Ni WK et al (2013) Combined analysis of serum gamma-glutamyl transferase isoenzyme II, alpha-L-fucosidase and alpha-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med 5:89\u201394","journal-title":"Exp Ther Med"},{"key":"2768_CR41","doi-asserted-by":"publisher","first-page":"10944","DOI":"10.3748\/wjg.v20.i31.10944","volume":"20","author":"XS Xu","year":"2014","unstructured":"Xu XS, Wan Y, Song SD, Chen W, Miao RC, Zhou YY et al (2014) Model based on gamma-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol 20:10944\u201310952","journal-title":"World J Gastroenterol"},{"key":"2768_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijsu.2016.10.033","volume":"36","author":"SJ Wu","year":"2016","unstructured":"Wu SJ, Lin YX, Ye H, Xiong XZ, Li FY, Cheng NS (2016) Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection. Int J Surg 36:143\u2013151","journal-title":"Int J Surg"},{"key":"2768_CR43","doi-asserted-by":"publisher","first-page":"9957","DOI":"10.3748\/wjg.v21.i34.9957","volume":"21","author":"R Huang","year":"2015","unstructured":"Huang R, Yang CC, Liu Y, Xia J, Su R, Xiong YL et al (2015) Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol 21:9957\u20139965","journal-title":"World J Gastroenterol"},{"key":"2768_CR44","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1017\/S1041610208006790","volume":"20","author":"BB Yavuz","year":"2008","unstructured":"Yavuz BB, Yavuz B, Halil M, Cankurtaran M, Ulger Z, Cankurtaran ES et al (2008) Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer\u2019s disease. Int Psychogeriatr 20:815\u2013823","journal-title":"Int Psychogeriatr"},{"key":"2768_CR45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/liv.12311","volume":"34","author":"EM Koehler","year":"2014","unstructured":"Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A et al (2014) Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int 34:296\u2013304","journal-title":"Liver Int"},{"key":"2768_CR46","doi-asserted-by":"publisher","first-page":"818570","DOI":"10.1155\/2015\/818570","volume":"2015","author":"G Koenig","year":"2015","unstructured":"Koenig G, Seneff S (2015) Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease Risk. Dis Markers 2015:818570","journal-title":"Dis Markers"},{"key":"2768_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00008390-199802000-00007","volume":"8","author":"I Melezinek","year":"1998","unstructured":"Melezinek I, Borovansky J, Elleder M, Bubnova E (1998) Tumour tissue is a source of gamma-glutamyl transpeptidase sialoform in the sera of melanoma-bearing mice. Melanoma Res 8:39\u201345","journal-title":"Melanoma Res"},{"key":"2768_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/jhep.2002.30277","volume":"35","author":"E Obrador","year":"2002","unstructured":"Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, Pellicer JA et al (2002) Gamma-glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 35:74\u201381","journal-title":"Hepatology"},{"key":"2768_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0009-8981(88)90138-6","volume":"177","author":"L Sacchetti","year":"1988","unstructured":"Sacchetti L, Castaldo G, Cimino L, Budillon G, Salvatore F (1988) Diagnostic efficiency in discriminating liver malignancies from cirrhosis by serum gamma-glutamyltransferase isoforms. Clin Chim Acta 177:167\u2013172","journal-title":"Clin Chim Acta"},{"key":"2768_CR50","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/clinchem\/42.8.1263","volume":"42","author":"G Castaldo","year":"1996","unstructured":"Castaldo G, Oriani G, Lofrano MM, Cimino L, Topa M, Budillon G et al (1996) Differential diagnosis between hepatocellular carcinoma and cirrhosis through a discriminant function based on results for serum analytes. Clin Chem 42:1263\u20131269","journal-title":"Clin Chem"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02768-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02768-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:06:38Z","timestamp":1616173598000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02768-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2768"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02768-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Medical Faculty of University T\u00fcbingen ethical committee (436\/2017BO2). The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}